Relief Therapeutics Holding SA (SWX: RLF)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 45.77M |
| Revenue (ttm) | 8.60M |
| Net Income (ttm) | -46.24M |
| Shares Out | 12.54M |
| EPS (ttm) | -3.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,265 |
| Average Volume | 28,391 |
| Open | 3.710 |
| Previous Close | 3.710 |
| Day's Range | 3.690 - 3.750 |
| 52-Week Range | 1.055 - 7.600 |
| Beta | -14.50 |
| RSI | 43.31 |
| Earnings Date | Apr 1, 2025 |
About SWX: RLF
Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disor... [Read more]
Financial Performance
In 2023, RLF's revenue was 6.03 million, a decrease of -0.79% compared to the previous year's 6.08 million. Losses were -98.18 million, 93.3% more than in 2022.
Financial StatementsNews
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Sale of GOLIKE® Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELI...
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, un...
Relief Therapeutics advances merger talks with Renexxion
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to deliverin...
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU Patients Results Expected to Promote Awareness and Adoption of PKU GOLIKE ® GENEVA, SWITZERLAND / ACCESSWIRE / De...
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation GENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF)...
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...
Relief Therapeutics signs letter of intent with Renexxion for reverse merger
Relief Therapeutics signs non-binding letter of intent with Renexxion for a reverse merger, strengthening their competitive position in biotech industry.
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering i...
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...
Relief Therapeutics gains on proof-of-concept data for antimicrobial agent
Relief gains as experimental therapy performs on par with BioMarin’s Kuvan
Relief Therapeutics (RLFTF) stock gains on positive data for RLF-OD032, an experimetal therapy targeted at BioMarin's (BMRN) phenylketonuria drug Kuvan. Read more here.
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
GENEVA, SWITZERLAND / ACCESSWIRE / September 18, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to deliverin...
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...
Relief Therapeutics reports 1H results
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined ope...
Relief Therapeutics Secures up to $11 Million from Royalty Sales
Non-dilutive funding to support RLF-TD011 clinical development and pipeline advancement GENEVA, SWITZERLAND / ACCESSWIRE / August 5, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:...
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to de...
Relief Therapeutics Announces Executive Changes
GENEVA, SWITZERLAND / ACCESSWIRE / June 3, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to del...
Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innova...
Relief Therapeutics has Published its Annual Report
GENEVA, SWITZARLAND / ACCESSWIRE / April 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatmen...
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESSWIRE / April 26, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF, RLFTY) (Relief Therapeutics, or the C...
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
Relief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors Overhaul GENEVA, SWITZERLAND / ACCESSWIRE / March 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF...
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering in...
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
3-year CHF 50 million capital commitment from GEM Relief advances strategic transformation GENEVA, SWITZERLAND / ACCESSWIRE / February 28, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(...